Paper37623652
Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers.
Anisuzzman M and 3 others. J Funct Biomater, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers. Papers, record 37623652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37623652
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-Tumor Activity of Novel Nimotuzumab-Functionalized Gold Nanoparticles as a Potential Immunotherapeutic Agent against Skin and Lung Cancers.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30318080 | Nimotuzumab: beyond the EGFR signaling cascade inhibition. | Semin Oncol | 2018 | https://conductscience.org/library/papers/30318080 | PubMed |
| 2 | 28741619 | Pancreatic Cancer: EGFR inhibition is effective against KRAS-wild-type disease. | Nat Rev Clin Oncol | 2017 | https://conductscience.org/library/papers/28741619 | PubMed |
| 3 | 20410458 | Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20410458 | PubMed |
| 4 | 28674498 | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. | Front Pharmacol | 2017 | https://conductscience.org/library/papers/28674498 | PubMed |
| 5 | 34294133 | Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34294133 | PubMed |
| 6 | 23631767 | Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. | ACS Nano | 2013 | https://conductscience.org/library/papers/23631767 | PubMed |
| 7 | 28347065 | Conjugation of Polymer-Coated Gold Nanoparticles with Antibodies-Synthesis and Characterization. | Nanomaterials (Basel) | 2015 | https://conductscience.org/library/papers/28347065 | PubMed |
| 8 | 30004227 | Characterizing the Surface Coverage of Protein-Gold Nanoparticle Bioconjugates. | Bioconjug Chem | 2018 | https://conductscience.org/library/papers/30004227 | PubMed |
| 9 | 29504398 | Biomimetic Viruslike and Charge Reversible Nanoparticles to Sequentially Overcome Mucus and Epithelial Barriers for Oral Insulin Delivery. | ACS Appl Mater Interfaces | 2018 | https://conductscience.org/library/papers/29504398 | PubMed |
| 10 | 33257670 | Enhanced dispersion stability of gold nanoparticles by the physisorption of cyclic poly(ethylene glycol). | Nat Commun | 2020 | https://conductscience.org/library/papers/33257670 | PubMed |
| 11 | 31554850 | Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence. | Sci Rep | 2019 | https://conductscience.org/library/papers/31554850 | PubMed |
| 12 | 31921818 | Cytotoxicity-Related Bioeffects Induced by Nanoparticles: The Role of Surface Chemistry. | Front Bioeng Biotechnol | 2019 | https://conductscience.org/library/papers/31921818 | PubMed |
| 13 | 32945225 | Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy. | Nanomedicine (Lond) | 2020 | https://conductscience.org/library/papers/32945225 | PubMed |
| 14 | 19803497 | Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies. | Anal Chem | 2009 | https://conductscience.org/library/papers/19803497 | PubMed |
| 15 | 32657634 | Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab. | Int J Radiat Biol | 2020 | https://conductscience.org/library/papers/32657634 | PubMed |
| 16 | 9449346 | Correlation between surface morphology and surface forces of protein A adsorbed on mica. | Biophys J | 1998 | https://conductscience.org/library/papers/9449346 | PubMed |
| 17 | 21150278 | Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. | Cancer Biol Ther | 2011 | https://conductscience.org/library/papers/21150278 | PubMed |
| 18 | 20121172 | One-phase synthesis of water-soluble gold nanoparticles with control over size and surface functionalities. | Langmuir | 2010 | https://conductscience.org/library/papers/20121172 | PubMed |
| 19 | 24990295 | Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model. | Nanotechnology | 2014 | https://conductscience.org/library/papers/24990295 | PubMed |
| 20 | 31698869 | Tumor Targeting by Monoclonal Antibody Functionalized Magnetic Nanoparticles. | Nanomaterials (Basel) | 2019 | https://conductscience.org/library/papers/31698869 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40124344 | Treatment of lung diseases via nanoparticles and nanorobots: Are these viable alternatives to overcome current treatments? | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40124344 | PubMed |
| 39940134 | Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting. | Nanomaterials (Basel) | 2025 | https://conductscience.org/library/papers/39940134 | PubMed |
| 37803407 | Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37803407 | PubMed |
| 37762316 | An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762316 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37623652
GET https://conductscience.org/api/papers/v1/37623652/references?page=2